Printer Friendly

Astellas Pharma, FibroGen Conclude Licensing Agreement for Oral Anemia Treatments.

Tokyo, Japan, May 2, 2006 - (JCN) - Astellas Pharma and FibroGen jointly have signed an exclusive licensing agreement for FG-2216 and FG-4592, drug candidates for anemia developed by FibroGen. FG-2216 and FG-4592 have a property to increase the production of endogenous erythropoietin (EPO), a kind of hemopoietic factors.

Under the agreement terms, Astellas Pharma will be licensed to develop and market the agents in Europe, the Commonwealth of Independent States (CIS), the Middle East and South Africa. The company will make an upfront payment of $300 million and development milestone payments totaling $465 million, as well as purchasing newly-issued shares of FibroGen at $50 million.

Going forward, Astellas Pharma will participate in clinical trials conducted in Europe and the US. Specifically, the two companies plan to start late phase II trials for renal anemia in the first half of 2006. They also plan to launch trials for anemia associated with cancer chemotherapy and cancerous anemia.

The agents will be available in Europe by 2012. Regarding FG-2216, Astellas Pharma has obtained an exclusive right to develop and market in Japan. Currently, the company is carrying out phase I trials for renal anemia associated with chronic renal failure in Japan.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:May 3, 2006
Previous Article:Denka Seiken to Construct Influenza Vaccine Manufacturing Facility in Niigata.
Next Article:Golden Week in Japan.

Related Articles
Astellas Pharma, Theravance to Enter into Licensing Agreement for Investigational Antibiotic Telavancin.
Astellas Pharma Sues Toyo Pharmar and Aska Pharmaceutical for Patent Infringement.
Astellas Pharma, XenoPort Conclude Licensing Agreement for XP13512 Analgesic Agent.
Astellas Pharma Receives FDA Approval for Hyponatremia Drug VAPRISOL.
Astellas Pharma, Toyama Chemical Agree on Joint Development of Quinolone Antibiotic T-3811 in Japan.
Astellas Pharma, Ferring Pharmaceuticals Sign Licensing Agreement for Degarelix, Prostate Cancer Agent.
Astellas and Toyama Chemical Announce Basic Licensing Agreement on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811.
Ilypsa and Astellas Enter a Licensing Agreement on ILY101 for Treatment of Hyperphosphatemia in Japan.
Astellas Discontinues Development of Immunosuppressant FK778.
Astellas Transfers Three European Plants to Temmler Group, German Pharmaceutical Company.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters